PD-L1 Expression and Its Association With p16 in Head and Neck Squamous Cell Carcinoma in Southwestern Uganda

References

• Ling DC, Bakkenist CJ, Ferris RL, Clump DA. Role of immunotherapy in head and neck cancer. Elsevier. 2018;12–16.
   Google Scholar
• Harrington KJ, Burtness B, Greil R, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the Phase III KEYNOTE-048 study. J Clin Oncol. 2023;41(4):790. doi:10.1200/JCO.21.02508
   PubMed Web of Science ®Google Scholar
• Mishra PS, Sidhu A, Dwivedi G, Mulajker DS, Awasthi S. Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry. Indian J Cancer. 2021.
   PubMed Web of Science ®Google Scholar
• Downes MR, Slodkowska E, Katabi N, Jungbluth AA, Xu B. Inter‐and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. Histopathology. 2020;76(2):191–200. doi:10.1111/his.13946
   PubMed Web of Science ®Google Scholar
• Schneider S, Kadletz L, Wiebringhaus R, et al. PD‐1 and PD‐L1 expression in HNSCC primary cancer and related lymph node metastasis–impact on clinical outcome. Histopathology. 2018;73(4):573–584. doi:10.1111/his.13646
   PubMed Web of Science ®Google Scholar
• Ock C-Y, Kim S, Keam B, et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget. 2016;7(13):15901. doi:10.18632/oncotarget.7431
   PubMedGoogle Scholar
• Chureemas T, Larbcharoensub N, Juengsamarn J, et al. Prevalence, pattern, and impact of PD-L1 expression and HPV-status in head and neck squamous cell carcinoma. Ann Oncol. 2016;27:vi337. doi:10.1093/annonc/mdw376.30
   Google Scholar
• Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143(3):330–337. doi:10.5858/arpa.2018-0043-OA
   PubMed Web of Science ®Google Scholar
• Lenouvel D, González-Moles MÁ, Talbaoui A, et al. An update of knowledge on PD‐L1 in head and neck cancers: physiologic, prognostic and therapeutic perspectives. Oral Dis. 2020;26(3):511–526. doi:10.1111/odi.13088
   PubMed Web of Science ®Google Scholar
• Abcam. Recombinant Anti-PD-L1 Antibody [EPR19759] (ab213524); 2022.
   Google Scholar
• Kim HS, Lee JY, Lim SH, et al. Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma. Cancer Res Treat. 2016;48(2):527–536. doi:10.4143/crt.2015.249
   PubMed Web of Science ®Google Scholar
• Ou D, Adam J, Garberis I, et al. Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio-or chemo-radiotherapy. Oncoimmunology. 2017;6(9):e1341030. doi:10.1080/2162402X.2017.1341030
   PubMed Web of Science ®Google Scholar
• Chen S-W, S-H L, Shi D-B, et al. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance. Int J Biol Markers. 2019;34(4):398–405. doi:10.1177/1724600819884722
   PubMed Web of Science ®Google Scholar
• Kim T, Jung S-H, Kim S-K, Kwon HJ. P16 expression and its association with PD-L1 expression and FOXP3-positive tumor infiltrating lymphocytes in head and neck squamous cell carcinoma. Mol Cellular Toxicol. 2019;15(2):137–143. doi:10.1007/s13273-019-0017-9
   Web of Science ®Google Scholar
• Nabukenya J, Hadlock TA, Arubaku W. Head and neck squamous cell carcinoma in Western Uganda: disease of uncertainty and poor prognosis. Oto Open. 2018;2(1):2473974X18761868. doi:10.1177/2473974X18761868
   PubMedGoogle Scholar
• Kabagenyi F, Otiti J, Namwagala J, Kamulegeya A, Kalungi S. A descriptive study of human papilloma virus in upper aero-digestive squamous cell carcinoma at Uganda cancer institute assessed by P16 immunohistochemistry. Cancers of the Head Neck. 2020;5:1–9. doi:10.1186/s41199-020-00057-3
   PubMedGoogle Scholar
• Chen SC, Chang PMH, Wang HJ, Tai SK, Chu PY, Yang MH. PD‑L1 expression is associated with p16INK4A expression in non‑oropharyngeal head and neck squamous cell carcinoma. Oncol Lett. 2018;15(2):2259–2265. doi:10.3892/ol.2017.7564
   PubMed Web of Science ®Google Scholar
• Udall M, Rizzo M, Kenny J, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn. Pathol. 2018;13(1):1–11. doi:10.1186/s13000-018-0689-9
   PubMedGoogle Scholar
• Lyu X, Zhang M, Li G, Jiang Y, Qiao Q. PD-1 and PD-L1 expression predicts radiosensitivity and clinical outcomes in head and neck cancer and is associated with HPV infection. J Cancer. 2019;10(4):937. doi:10.7150/jca.27199
   PubMed Web of Science ®Google Scholar
• Shestakova A, Tarabay J, Burtsev A, et al. Increased PD-L1 and p16 expression are common in oropharyngeal squamous cell carcinoma. Future Science OA. 2021;7(9):FSO768. doi:10.2144/fsoa-2021-0039
   PubMed Web of Science ®Google Scholar
• Polesel J, Menegaldo A, Tirelli G, et al. Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: a Meta-Analysis. Front Oncol. 2021;11.
   Google Scholar
• Badoual C, Hans S, Merillon N, et al. PD-1–expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013;73(1):128–138. doi:10.1158/0008-5472.CAN-12-2606
   PubMed Web of Science ®Google Scholar
• Blatt S, Krüger M, Rump C, Zimmer S, Sagheb K, Künzel J. Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma. PLoS One. 2022;17(5):e0269136. doi:10.1371/journal.pone.0269136
   PubMed Web of Science ®Google Scholar
• Widmaier M, Wiestler T, Walker J, et al. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis. Mod Pathol. 2020;33(3):380–390. doi:10.1038/s41379-019-0349-y
   PubMed Web of Science ®Google Scholar